Key result
Glucocorticoid therapy in FH-I lowers aldosterone-renin ratios but fails to restore angiotensin II responsiveness.
Why the study?
In familial hyperaldosteronism type I (FH-I), glucocorticoid treatment suppresses adrenocorticotrophic hormone-regulated hybrid gene expression and corrects hyperaldosteronism, but it was unknown whether wild-type aldosterone synthase genes released from chronic suppression can function normally.
Observational (n=11)
Glucocorticoids may incompletely normalize aldosterone regulation in FH-I; leaves open need for adjunctive therapies or outcome trials.
BACKGROUND: In familial hyperaldosteronism type I (FH-I), glucocorticoid treatment suppresses adrenocorticotrophic hormone-regulated hybrid gene expression and corrects hyperaldosteronism. OBJECTIVE: To determine whether the wild-type aldosterone synthase genes, thereby released from chronic suppression, are capable of functioning normally. METHODS: We compared mid-morning levels of plasma potassium, plasma aldosterone, plasma renin activity (PRA) and aldosterone: PRA ratios, measured with patients in an upright position, and responsiveness of aldosterone levels to infusion of angiotensin II (AII), for 11 patients with FH-I before and during long-term (0.8-14.3 years) treatment with 0.25-0.75 mg/day dexamethasone or 2.5-10 mg/day prednisolone. RESULTS: During glucocorticoid treatment, hypertension was corrected in all. Potassium levels, which had been low (< 3.5 mmol/l) in two patients before treatment, were normal in all during treatment (mean 4.0+/-0.1 mmol/l, range 3.5-4.6). Aldosterone levels during treatment [13.2+/-2.1 ng/100 ml (mean+/-SEM)] were lower than those before treatment (20.1+/-2.5 ng/100 ml, P< 0.05). PRA levels, which had been suppressed before treatment (0.5+/-0.2 ng/ml per h), were unsuppressed during treatment (5.1+/-1.5 ng/ml per h, P< 0.01) and elevated (> 4 ng/ml per h) in six patients. Aldosterone: PRA ratios, which had been elevated (> 30) before treatment (101.1+/-25.9), were much lower during treatment (4.1+/-1.0, P< 0.005) and below normal (< 5) in eight patients. Surprisingly, aldosterone level, which had not been responsive (< 50% rise) to infusion of AII for all 11 patients before treatment, remained unresponsive for 10 during treatment. CONCLUSIONS: Apparently regardless of duration of glucocorticoid treatment in FH-I, aldosterone level remains poorly responsive to AII, with a higher than normal PRA and a low aldosterone: PRA ratio. This is consistent with there being a persistent defect in functioning of wild-type aldosterone synthase gene.
No takes yet. Share an insight, caveat, or question.
Stowasser et al. (1997) conducted an observational in Familial hyperaldosteronism type I (FH-I) (n=11). Glucocorticoid treatment (dexamethasone or prednisolone) vs. Before treatment (baseline) was evaluated on Aldosterone:plasma renin activity (PRA) ratio and responsiveness of aldosterone levels to angiotensin II (AII) infusion (p=<0.005). Long-term glucocorticoid treatment in FH-I lowered aldosterone:PRA ratios (4.1 vs 101.1, P<0.005), but aldosterone remained unresponsive to angiotensin II in 10 of 11 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: